Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Braintree, MA

    Search
    Braintree, MA
    Show Map
    Map View
    Braintree, MA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      191 Clinical Trials near Braintree, MA

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      CTX-009 + Paclitaxel for Biliary Tract Cancer

      Boston, Massachusetts
      This trial tests a new drug (CTX-009) combined with chemotherapy in patients with advanced biliary tract cancers who have already had other treatments and cannot have surgery. The treatment aims to boost the immune system and stop cancer cell growth.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Diseases, CNS Metastasis, Others
      Must Not Be Taking:Anticoagulants, NSAIDs, Antiplatelets

      150 Participants Needed

      CSL300 for Kidney Failure

      Boston, Massachusetts
      This trial is testing CSL300, a new treatment, to see if it helps people with heart disease or diabetes who are on dialysis. The study aims to find the right dose and check if it improves heart health by reducing inflammation.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Abnormal LFTs, Life-threatening Disease, Others
      Must Not Be Taking:Immunosuppressants

      2310 Participants Needed

      RYZ101 for Neuroendocrine Tumors

      Boston, Massachusetts
      This trial tests RYZ101, a new drug, in patients with advanced GEP-NETs that haven't responded to previous treatments. The drug aims to target specific receptors on the tumor cells to stop their growth.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Resistant Hypertension, Uncontrolled Diabetes, Others
      Must Not Be Taking:High-dose Glucocorticoids

      288 Participants Needed

      Eye Patching for Intermittent Exotropia

      Boston, Massachusetts
      This trial aims to see if covering one eye all day helps children with an eye condition where one eye turns outward.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:3 - 8

      Key Eligibility Criteria

      Disqualifiers:Prior Strabismus Surgery, Diplopia, Paretic Strabismus, Craniofacial Malformations, Others

      73 Participants Needed

      Mirvetuximab + Bevacizumab for Ovarian Cancer

      Boston, Massachusetts
      GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Other Cancers, Cardiac Disease, Infections, Others
      Must Be Taking:Platinum-based Chemotherapy

      520 Participants Needed

      Efzofitimod for Sarcoidosis

      Boston, Massachusetts
      This trial is testing a new treatment to help adults with a lung disease called pulmonary sarcoidosis. These patients are already on other treatments but may need more help. The new treatment aims to improve their condition.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Fibrosis, Hypertension, Cardiac Sarcoidosis, Others
      Must Be Taking:Oral Corticosteroids

      268 Participants Needed

      Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Breast Cancer

      Boston, Massachusetts
      This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infection, Autoimmune, Others
      Must Not Be Taking:Topoisomerase Inhibitors

      443 Participants Needed

      5-Fluorouracil + Calcipotriene Cream for Skin Cancer

      Boston, Massachusetts
      This trial compares a standard cancer-killing cream with a new, potentially more effective cream. It targets patients with less aggressive skin cancers. The new cream might work better by combining two ingredients to kill cancer cells and prevent new ones from forming.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Immunosuppression, Genetic Disorders, Pregnancy, Others

      200 Participants Needed

      Oral Ketamine for Sickle Cell Pain

      Boston, Massachusetts
      The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioids. There is a need for improved non-opioid analgesia for patients experiencing sickle-cell crises in the hospital and prehospital setting, as children and adolescents with sickle cell disease who experience sickle-cell crises often have severe pain that is not well controlled by high dose opioids, leading to poor pain management and opioid-related side effects. The study will begin when patients are admitted to the Emergency Department of Boston Children's Hospital for treatment of a sickle-cell crisis. Oral ketamine will be administered every 8 hours for the next 48 hours. Patients will have continuous cardiorespiratory monitoring for the duration of the study, as per routine care, as well as monitoring by the hospital's Acute Pain Service at least twice daily for pain management and side effects of pain treatment. At the end of the 48-hour study duration, patients will discuss with the Pain Service and Hematology Service whether to continue oral ketamine, change to intravenous ketamine, or discontinue ketamine based on clinical indications such as level of pain and sedation while on opioids.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12 - 24

      Key Eligibility Criteria

      Disqualifiers:Ketamine Side Effects, Patient Refusal

      10 Participants Needed

      SmartSteps Intervention for HIV Prevention

      Boston, Massachusetts
      This is a single-arm, observational study of HIV-negative MSM with substance use disorder. Those who meet pre-screening criteria will attend a Screening Visit (Visit 1), where the informed consent process will be conducted and study eligibility will be confirmed. Eligible participants will attend three additional visits over the course of the study - the Enrollment Visit (Visit 2), Month 1 Visit (Visit 3), and Month 2 Visit (Visit 4). Participants will take one PrEP digital pill per day, for 60 days total, while using the digital pill system (DPS) and Beiwe, a digital phenotyping app. On nonadherent days, participants will receive brief surveys prompting them to report the reasons for their missed dose, as well as their engagement in substance use and sexual activity. Timeline followback will be conducted at the Month 1 and Month 2 Visits to understand the context of any nonadherence. Qualitative user experience exit interviews and dried blood spots (DBS) will be conducted at the Month 2 Visit.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Crohn's, Ulcerative Colitis, Others
      Must Be Taking:PrEP

      40 Participants Needed

      BPN14770 for Fragile X Syndrome

      Boston, Massachusetts
      This trial is testing a medication called BPN14770 in men aged 18 to 45 who have Fragile X Syndrome. The medication aims to improve brain function by balancing chemicals that help with thinking and memory.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 45
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Renal Impairment, Hepatic Impairment, Substance Abuse, Others

      171 Participants Needed

      Taldefgrobep Alfa for Spinal Muscular Atrophy

      Boston, Massachusetts
      This trial will test if taldefgrobep alfa can help people with SMA who are already on other treatments. The drug works by blocking a protein that stops muscle growth, potentially making muscles stronger and improving movement. Taldefgrobep alfa has shown promise in increasing muscle mass and function in SMA patients.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4 - 21

      Key Eligibility Criteria

      Disqualifiers:Respiratory Insufficiency, Spinal Fusion, Others
      Must Be Taking:Nusinersen, Risdiplam, Onasemnogene

      269 Participants Needed

      Abatacept for Myocarditis

      Boston, Massachusetts
      This Trial tests if abatacept can reduce serious heart problems in patients with heart inflammation caused by cancer treatments. Abatacept calms the immune system by preventing certain immune cells from becoming fully active, reducing inflammation and damage. Abatacept has been approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis, with or without methotrexate.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Infections, Pregnancy, Recent Cardiac Events, Others
      Must Be Taking:Solumedrol

      390 Participants Needed

      Depemokimab for Hypereosinophilic Syndrome

      Boston, Massachusetts
      This trial is testing a new medication called depemokimab for adults with Hypereosinophilic Syndrome (HES) who are not responding well to their current treatments. The medication aims to lower the number of certain white blood cells that cause symptoms to worsen. Participants will either receive depemokimab or continue their usual treatment.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Infections, Cancer, Cardiovascular Disease, Others
      Must Be Taking:Standard HES Therapy

      123 Participants Needed

      Orca-T for Blood Cancers

      Boston, Massachusetts
      This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies. This posting represents the Phase III component of Precision-T. The Precision-T Ph1b component is described under NCT04013685.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Prior Allogeneic HCT, HIV, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressive Therapy

      187 Participants Needed

      Linsitinib for Thyroid Eye Disease

      Boston, Massachusetts
      This trial studies the safety and effectiveness of linsitinib, an oral medication taken regularly, in patients with moderate to severe thyroid eye disease. Linsitinib works by blocking a protein that contributes to the disease, aiming to reduce symptoms and improve eye health.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Optic Neuropathy, Corneal Decompensation, Others
      Must Not Be Taking:Glucocorticoids, IGF-1R Inhibitors

      90 Participants Needed

      Pegvaliase for Phenylketonuria

      Boston, Massachusetts
      This trial is testing pegvaliase injections in adolescents with PKU. The goal is to see if these injections are safe and effective. Pegvaliase helps the body break down a harmful substance that people with PKU cannot process on their own. Pegvaliase is a newer treatment for PKU, following earlier treatments like dietary restriction and sapropterin.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Organ Transplant, HIV, Hepatitis, Others
      Must Not Be Taking:PKU Treatments, PEG Injectables

      55 Participants Needed

      BI 907828 vs Doxorubicin for Liposarcoma

      Boston, Massachusetts
      This trial is for adults with advanced dedifferentiated liposarcoma who are not receiving other treatments. It compares a new drug, brigimadlin (BI 907828), which blocks a protein that helps cancer grow, with doxorubicin, an existing drug that damages cancer cell DNA. Participants receive either brigimadlin as tablets or doxorubicin through a vein. Doctors monitor tumor size and health regularly. The new drug aims to be effective and less toxic compared to conventional treatments.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:TP53 Mutation, Other Malignancies, Others
      Must Not Be Taking:Anthracyclines

      400 Participants Needed

      CGT9486 + Sunitinib for GIST

      Boston, Massachusetts
      This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner. Additionally, a drug-drug interactions substudy will investigate the potential for CGT9486 to be a CYP3A4 inducer in approximately 16 patients who have received at least one prior line of therapy for GIST.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, HIV, Hepatitis, Others
      Must Be Taking:Tyrosine Kinase Inhibitors

      442 Participants Needed

      Chemotherapy Tailored by ctDNA Status for Colon Cancer

      Boston, Massachusetts
      This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Prior Chemotherapy, Others
      Must Not Be Taking:Antidepressants, Anticonvulsants

      1912 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Trial

      Metreleptin for Partial Lipodystrophy

      Boston, Massachusetts
      This trial tests the safety and effectiveness of daily injections of metreleptin for people with Partial Lipodystrophy. The treatment aims to replace a missing hormone to help their bodies manage fat and sugar levels better. Metreleptin is approved by the United States Food and Drug Administration for the treatment of generalized forms of lipodystrophy and has shown improvement in many patients.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Previous Metreleptin, High Leptin, APL, Others

      69 Participants Needed

      Zatolmilast for Fragile X Syndrome

      Boston, Massachusetts
      This trial is testing a medication called BPN14770 in boys with fragile X syndrome. The study aims to see how the medication moves through their bodies and if it helps with their symptoms.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3
      Age:9 - 18
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Renal, Hepatic, Psychiatric, Others

      163 Participants Needed

      Remibrutinib vs Teriflunomide for Multiple Sclerosis

      Boston, Massachusetts
      This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, CNS Disease, Substance Abuse, Others
      Must Not Be Taking:Leflunomide, Methotrexate, CYP3A4 Inhibitors

      800 Participants Needed

      Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer

      Boston, Massachusetts
      Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Heart Disease, Liver Disease, HIV, Others
      Must Not Be Taking:Topoisomerase Inhibitors

      705 Participants Needed

      Responsive Neurostimulation for Generalized Epilepsy

      Boston, Massachusetts
      To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Psychosis, Major Depression, Others
      Must Be Taking:Antiseizure Medications

      100 Participants Needed

      Remibrutinib vs Teriflunomide for Multiple Sclerosis

      Boston, Massachusetts
      This trial compares remibrutinib and teriflunomide in patients with relapsing multiple sclerosis. It aims to find out which medication is more effective and safer. Both drugs work by controlling the immune system to reduce relapses. Teriflunomide is an approved treatment for adults with this condition.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, CNS Disease, Substance Abuse, Others
      Must Not Be Taking:Leflunomide, Methotrexate, CYP3A4 Inhibitors, Others

      800 Participants Needed

      Evogliptin for Aortic Stenosis

      Boston, Massachusetts
      This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have three phases: Screening Period (up to 4 weeks), Treatment Period (104 weeks), and Follow-Up Period (2-4 weeks). Total Study Duration is112 Weeks.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:35+

      Key Eligibility Criteria

      Disqualifiers:Severe Valve Disease, Heart Failure, Diabetes, Others
      Must Not Be Taking:DPP4 Inhibitors, Vitamin K, CYP3A4 Drugs

      580 Participants Needed

      NRTX-1001 Neural Cell Therapy for Epilepsy

      Boston, Massachusetts
      This trial tests if injecting special brain cells into the brain can help patients with hard-to-treat epilepsy. The new cells release a calming chemical to reduce seizures. Patients will also take medicines to prevent their bodies from rejecting the new cells.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Neurologic Disease, Immunodeficiency, Psychiatric Disorders, Others
      Must Be Taking:ASDs

      88 Participants Needed

      REC-2282 for Meningioma

      Boston, Massachusetts
      This trial is testing a new drug called REC-2282 to see if it can help treat specific brain tumors in patients who haven't responded to other treatments. The study will check if the drug can slow down or stop the growth of these tumors.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Terminated
      Trial Phase:Phase 2, 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Pregnancy, Others
      Must Not Be Taking:Anti-tumor Agents, Investigational Drugs

      25 Participants Needed

      Cell Therapy for Duchenne Muscular Dystrophy

      Boston, Massachusetts
      This trial tests a cell therapy called CAP-1002 in boys and young men with Duchenne muscular dystrophy. The therapy involves giving special cells through an IV to help improve muscle function. The goal is to see if this treatment can repair or regenerate damaged muscles.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:10+
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Low LVEF, High BMI, Others
      Must Be Taking:Glucocorticoids

      104 Participants Needed

      1...567

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Braintree, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Braintree, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Braintree, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Braintree, MA is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Braintree, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Braintree, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Braintree, MA?

      Most recently, we added Deucravacitinib vs Ustekinumab for Plaque Psoriasis, Bionetide for Rett Syndrome and IFx-Hu2.0 + Pembrolizumab for Skin Cancer to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards in Braintree, MA?

      The clinics in Braintree, MA currently recognized as Power Preferred are: Copley Clinical Research in Boston, Massachusetts Copley Clinical in Boston, Massachusetts Boston Clinical Trials in Roslindale, Massachusetts

      Popular Searches

      By Condition

      Depression Clinical Trials in Massachusetts

      Anxiety Clinical Trials in Massachusetts

      Schizophrenia Clinical Trials in Massachusetts

      ADHD Clinical Trials in Massachusetts

      Bipolar Disorder Clinical Trials in Massachusetts

      Multiple Sclerosis Clinical Trials in Massachusetts

      Autism Clinical Trials in Massachusetts

      Treatment Resistant Depression Clinical Trials in Massachusetts

      Borderline Personality Disorder Clinical Trials in Massachusetts

      Social Anxiety Disorder Clinical Trials in Massachusetts

      Parkinson's Disease Clinical Trials in Massachusetts

      Alzheimer's Disease Clinical Trials in Massachusetts

      By Location

      Clinical Trials near Boston, MA

      Clinical Trials near Worcester, MA

      Clinical Trials near Springfield, MA

      Clinical Trials near Burlington, MA

      Clinical Trials near Fall River, MA

      Clinical Trials near Cambridge, MA

      Clinical Trials near North Dartmouth, MA

      Clinical Trials near Newton, MA

      Clinical Trials near Waltham, MA

      Clinical Trials near Watertown, MA

      Clinical Trials near Belmont, MA

      Clinical Trials near Brockton, MA

      Other People Viewed

      By Subject

      Top Clinical Trials near Worcester, MA

      Top Clinical Trials near Hyannis, MA

      Top Clinical Trials near Haverhill, MA

      Top Clinical Trials near Foxboro, MA

      Top Clinical Trials near Framingham, MA

      Top Clinical Trials near Fitchburg, MA

      Top Clinical Trials near Fairhaven, MA

      Top Clinical Trials near Gloucester, MA

      Top Clinical Trials near Brookline, MA

      Top Clinical Trials near Charlestown, MA

      Top Clinical Trials near Brockton, MA

      Top Clinical Trials near Beverly, MA

      By Trial

      High Arabinose Diet for Gut Bacteria

      Sociocultural Influences on Pain Assessment

      EMR-Based Treatment for Neurological Disorders

      Alkaline Buffer Challenge for Asthma

      Liraglutide for MODY

      Continuous Glucose Monitoring for Type 2 Diabetes

      Chemotherapy for Neuroendocrine Cancer

      Pulmonary Function Testing for Neonatal Respiratory Disorders

      Brain Stimulation for Speech Improvement

      DBS TaT for Hepatitis C

      Soft Tissue Manipulation for Soreness

      Active Exercise for Pollution Exposure

      Related Searches

      Top Clinical Trials near Brandon, FL

      Top Clinical Trials near Brentwood, TN

      Fluvoxamine for Post-COVID Syndrome

      IPN10200 for Upper Limb Spasticity

      Tart Cherry Juice for Insomnia

      mHealth + Counseling for Alcoholism

      Exercise for Osteoarthritis

      Electrical Brain Stimulation for Parkinson's Disease

      Immunotherapy + Adoptive Cell Therapy for Melanoma

      Gamification for Heart Failure

      Anti-Cancer Viral Therapy + Chemoradiation for Esophageal Cancer

      Larynx Transplant for Post-Laryngectomy